Cuprina Holdings Announces It Has Completed the Set-up Of A Laboratory, Located in Saudi Arabia, Equipped To Manufacture The Company's Medifly Maggot Debridement Therapy For Treatment Of chronic Wounds And To Supply The therapy Across The Middle East And North Africa

uprina Holdings (Cayman) Limited (NASDAQ:CUPR) ("CUPR" or "the Company"), a biomedical and biotechnology company dedicated to the development and commercialization of products for the management of chronic wounds and infertility, as well as cosmeceuticals for the health and beauty sector, today announced that its indirect 49%-owned associate, Cuprina MENA Co. Ltd, had completed the set-up of a laboratory, located in Saudi Arabia, equipped to manufacture the company's MEDIFLY maggot debridement therapy for the treatment of chronic wounds and to supply the therapy across the Middle East and North Africa ("MENA") region.

Cuprina MENA is now working towards obtaining the regulatory approvals, including the Saudi Food and Drug Authority license and ISO 13485 certification, required in order to sell the therapy in the MENA region.

In another development, Cuprina MENA has secured exclusive rights from Biopharm UK Ltd ("BioPharm"), the world's leading provider of medicinal leeches, to sell these leeches across the Gulf Cooperation Council ("GCC") countries. 

Medicinal leeches are increasingly used in the GCC to treat diverse medical conditions including venous congestion, which is a buildup of blood in the veins, and to aid in tissue healing and circulation following reconstructive and microsurgery procedures. The leeches are also used to relieve symptoms of osteoarthritis as well as in veterinary surgery, especially to help treat polycythaemia vera, a chronic blood cancer.